Compare Hewlett Packard Enterprise Co (HPE) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hewlett Packard Enterprise Co vs BIO-TECHNE Corp — how do they compare? Hewlett Packard Enterprise Co trades at $54.78 (market cap $72.41B), while BIO-TECHNE Corp trades at $72.13 (market cap $11.24B). The key difference: Hewlett Packard Enterprise Co is far larger — about 6.4× BIO-TECHNE Corp's market cap, and Hewlett Packard Enterprise Co pays the higher dividend (1.04%). Which is the better fit depends on your goals.
| HPE | TECH | |
|---|---|---|
Market Cap | $72.41B | $11.24B |
Sector | Technology | Health |
52-Week High | $56.14 | $72.29 |
52-Week Low | $20.01 | $43.31 |
Enterprise Value | $88.36B | $11.32B |
Dividend Yield | 1.04% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HPE stock trades at $53.22, up 1.49% today, near its pivot point of $53, with bullish moving averages but overbought RSI signals. Recent earnings beats, including Q1 2026 EPS of $0.79 versus $0.535 expected, and a Morgan Stanley upgrade on August 10, 2026, highlight AI infrastructure demand strength. Revenue grew to $34.30B in 2025, though net income fell sharply to $57M due to high investing cash outflows.
The outlook is positive with a consensus price target of $69.81, implying 31% upside, supported by AI server trends. Risks include volatile cash flows, rising debt-to-asset ratio to 29.48% in 2025, and intense competition. Investors should weigh growth potential against execution risks in a high-valuation environment.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hewlett Packard Enterprise Co
Hewlett Packard Enterprise is an information technology vendor that provides hardware and software to enterprises. Its primary product lines are compute servers, storage arrays, and networking equipment.
Read more on HPE →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
